

# Multinational cooperation for vaccine development

Accelerating the licensure of Lassa vaccines, 25-26 Oct 2022- Abuja, Nigeria


*César Muñoz-Fontela, Bernhard Nocht Institute for Tropical Medicine  
and WHO R&D Blueprint*




**R&D**Blueprint

Powering research  
to prevent epidemics

# Vaccine development timelines



# Global collaboration= Speed



1- Immunogen (basic science)


2- Candidate selection

3- Preclinical phase (models)

Global collaboration speeds up vaccine development by **sharing information** and avoiding **duplication** and **bottlenecks**

# Umbrella= WHO Expert working groups

4




# Worldwide collaboration online

5



# MARVAC Expert Working Group

WHO R&D Blueprint Coordinated consortium to promote international collaboration for the development of MVD vaccines



# MARVAC Expert Working Group

## Principles

7

- 1- Sharing of assays and reagents
- 2- Promoting access to laboratory networks in MDV-endemic countries
- 3- Promoting structural support for preclinical development of upcoming MDV vaccines

# MARVAC role within the new WHO filovirus research roadmap (AFIRM)

## 1- Strategic goals

- 1- To establish a platform trial design for vaccines against Marburg and Sudan virus
- 2- To setup a WHO-coordinated consortium including regulators, developers and members of academia to accelerate the development of filovirus vaccines (WHO-MARVAC)
- 3- To foster the exploration of different vaccine platforms that incorporate different targets with the goal of developing multivalent vaccines.
- 4- To compile data on the duration of protective immunity after vaccination with EBOV vaccines and identify the correlates of protection involved to facilitate faster evaluation of promising vaccine candidates against other filoviruses.



# MARVAC role within the new WHO filovirus research roadmap (AFIRM)

## 2- Milestones

- 1- By 2025, clinical evaluation for vaccine candidates against Marburg and Sudan virus.
- 2- By 2030, obtain licensure for at least one vaccine against Marburg virus or Sudan virus.
- 3- By 2030, develop a broad-spectrum filovirus vaccine that is low cost, efficacious and safe.

# Thank you

**For more information please contact:**

César Muñoz-Fontela

[munozc@who.int](mailto:munozc@who.int)

@CesarMFontela

**WHO Headquarters in Geneva**

Avenue Appia 20

1202 Geneva

Telephone: +41-22-7912111

